Enhertu approved in the US as first tumour-agnostic HER2-directed therapy
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
International Business is expected to register double-digit growth in constant currency terms
The company plans to add 1700 beds by FY27 through the organic route
Reconfirms a relative bioavailability of 65 percent and significant savings when using DL-methionine
New leadership team announced at NATHEALTH Annual General Meeting 2024
Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
Vivity is the first and only wavefront-shaping IOL with Alcon’s proprietary X-WAVE Technology
The average time of dilation lasts three to eight hours
Subscribe To Our Newsletter & Stay Updated